In this article, we will list the 5 Best NASDAQ Stocks Under $5 to Buy Right Now. Please visit 10 Best NASDAQ Stocks Under $5 to Buy Right Now to see the extended list and the methodology behind it.
5. Compass Therapeutics Inc. (NASDAQ:CMPX)
Number of Hedge Fund Holders: 38
Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while G&A expenses climbed 41% to $6.9 million due to stock compensation and $1.0 million in pre-commercialization costs. The company ended the quarter with $195 million in cash and marketable securities, providing an anticipated capital runway into 2028.
The company is preparing for a BLA submission and an FDA meeting later this year for tovecimig, which recently received Orphan Drug Designation for biliary tract cancer/BTC. In a Phase 2/3 study, the tovecimig combination met its primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone. It also significantly improved median progression-free survival to 4.7 months compared to 2.6 months for the control group.
Compass Therapeutics Inc. (NASDAQ:CMPX) has also initiated cohort expansions for CTX-8371 across breast, lung, and lymphoma indications, with initial data scheduled for presentation at ASCO 2026. Additionally, a Phase 1 study has commenced for CTX-10726 in solid tumors, with initial data expected in Q4 2026. Finally, a Phase 2 trial for the company’s CD137 agonist, CTX-471, is on track to begin in H2 2026.
Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics for the treatment of various human diseases in the US.
4. MannKind Corporation (NASDAQ:MNKD)
Number of Hedge Fund Holders: 39
MannKind Corporation (NASDAQ:MNKD) is one of the best NASDAQ stocks under $5 to buy right now. On May 6, MannKind reported total revenues of $90.2 million for Q1 2026, marking a 15% increase compared to Q1 2025. This growth was driven by $15.5 million in net sales from Furoscix and a 9% increase in Tyvaso DPI royalties from United Therapeutics, which offset a 20% drop in collaboration revenues. Operating costs grew, with R&D expenses climbing 56% to $17.2 million and SG&A expenses rising 116% to $54.1 million due to the acquisition of scPharma and commercial launch preparations.
On the regulatory front, MannKind is approaching two key FDA action dates. The PDUFA date for the Afrezza inhaled insulin pediatric indication is set for May 29, while the Furoscix ReadyFlow Autoinjector has a target PDUFA date of July 26. To support these potential commercial expansions, the company has already built out its launch infrastructure and aligned its field-based teams.
In its development pipeline, MannKind Corporation (NASDAQ:MNKD) completed enrollment for the Phase 1b trial of Nintedanib DPI (MNKD-201) for idiopathic pulmonary fibrosis (IPF), with a Phase 2 trial expected to enroll its first patient in Q2 2026. Additionally, the company expanded its collaboration with United Therapeutics for Ralinepag DPI (MNKD-1501), receiving a $5 million payment to accelerate its development. Formulation work also continues for Bumetanide DPI (MNKD-701) to treat edema associated with heart and kidney disease.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.
3. Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Number of Hedge Fund Holders: 39
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy right now. On May 7, Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million ($0.42 per share). Driven by a recent realignment and lower headcount, R&D expenses fell to $31.5 million, and G&A expenses dropped to $17.1 million. The company held $144.4 million in cash at quarter-end, which jumps to $322.6 million on a pro forma basis following the $180 million sale of its Priority Review Voucher, extending its operational runway into Q2 2028.
The financial runway was boosted by the FDA’s accelerated approval of KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). This regulatory milestone granted Rocket a Rare Pediatric Disease Priority Review Voucher, which the company subsequently monetized for $180 million in non-dilutive proceeds.
In its clinical pipeline, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) reinitiated dosing in the pivotal Phase 2 trial of RP-A501 for Danon disease under a modified protocol, with a program update targeted for the second half of 2026. The company is also aligning with the FDA on a Phase 2 trial design for RP-A601 in arrhythmogenic cardiomyopathy, and expects first-patient dosing for its Phase 1 BAG3-dilated cardiomyopathy study in mid-2026.
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is a biotechnology company focused on genetic therapies for rare disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.
2. Newell Brands Inc. (NASDAQ:NWL)
Number of Hedge Fund Holders: 40
Newell Brands Inc. (NASDAQ:NWL) is one of the best NASDAQ stocks under $5 to buy right now. On May 1, Newell Brands reported Q1 2026 net sales of $1.5 billion, a slight 1.1% decline compared to the prior year period, with core sales dropping 3.5%. Despite a challenging macroeconomic backdrop, results exceeded internal expectations across all segments due to resilient consumer demand, increased product promotion, and improved deduction management. Operating margin expanded to 2.2% as productivity and pricing actions countered inflation, narrowing the GAAP net loss to $33 million, or $0.08 per share.
Segment performance was mixed, led by Learning & Development, which grew net sales by 3.8% to $594 million and expanded its normalized operating margin to 18.9%. Conversely, Home & Commercial Solutions sales fell 3.9% to $780 million, and Outdoor & Recreation sales dropped 3.8% to $175 million. Balance sheet health remained steady with $201 million in cash against $5.0 billion in total debt, while year-to-date operating cash outflow ticked up to $233 million due to elevated inventory levels.
Following the first-quarter over-delivery, management raised its full-year 2026 financial guidance. Full-year net sales are now projected between flat and 2% growth, with core sales expected at a range of negative 1% to positive 1% and normalized EPS adjusted upward to $0.56 to $0.60. Fueled by improving point-of-sale and market share trends, Newell Brands Inc. (NASDAQ:NWL) anticipates a definitive return to top-line growth in Q2.
Newell Brands Inc. (NASDAQ:NWL) is an American consumer goods company with a strong portfolio of brands such as Rubbermaid, Sharpie, Graco, Coleman, and more.
1. ZoomInfo Technologies Inc. (NASDAQ:GTM)
Number of Hedge Fund Holders: 43
ZoomInfo Technologies Inc. (NASDAQ:GTM) is one of the best NASDAQ stocks under $5 to buy right now. On May 11, ZoomInfo reported Q1 2026 GAAP revenue of $310.2 million, marking a 1.5% year-over-year increase. GAAP operating income rose 15% to $57.9 million with a 19% margin, while adjusted operating income grew 9% to $109.7 million, yielding a 35% margin. The company generated $114.7 million in cash flow from operations and $119.7 million in unlevered free cash flow, representing a 4% decline for both metrics compared to the prior year.
The company closed the quarter with 1,900 customers contributing $100,000 or more in ACV, an increase of 32 clients year-over-year but a sequential decline of 21 from the prior quarter. Upmarket clients represented 75% of total ACV, growing 5% year-over-year, while the company’s overall net revenue retention rate stood at 90%. Additionally, ZoomInfo utilized $90.5 million to repurchase 13.1 million shares of its common stock at an average price of $6.91 per share.
ZoomInfo Technologies Inc. (NASDAQ:GTM) lowered its full-year 2026 financial outlook, adjusting its GAAP revenue expectations to a range of $1.185 to $1.205 billion, down from its previous guidance of $1.247 to $1.267 billion. Full-year non-GAAP adjusted operating income is now projected between $437 and $447 million, while unlevered free cash flow guidance was trimmed to a range of $400 to $420 million. For Q2 2026, the company expects GAAP revenue between $300 and $303 million.
ZoomInfo Technologies Inc. (NASDAQ:GTM) operates a cloud-based platform that offers information on organizations and professionals for sales and marketing teams. The company’s platform covers sales leadership, sales development, marketing, demand generation, sales and marketing operations, and recruiting.
While we acknowledge the potential of GTM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GTM and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Performing NASDAQ Stocks According to Wall Street Analysts and 10 Worst Performing NASDAQ Stocks So Far in 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
